# Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

> **NCT07536282** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Newish Biotech (Wuxi) Co., Ltd.** · enrollment: 78 (estimated)

## Conditions studied

- Persistent HPV16 Infection

## Interventions

- **BIOLOGICAL:** NWRD09
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07536282
- **Lead sponsor:** Newish Biotech (Wuxi) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-09
- **Final completion:** 2027-11
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07536282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07536282, "Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT07536282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*